Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan Plus Berzosertib (M6620) vs Topotecan Alone in Relapsed Small-Cell Lung Cancer
NCT03896503Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib in small cell lung cancer (SCLC), Extrapulmonary Small Cell Carcinoma (EPSCC), sponsored by National Cancer Institute. Started Dec 2019; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
small cell lung cancer (SCLC)Extrapulmonary Small Cell Carcinoma (EPSCC)
Beyond the preview
Go deeper on NCT03896503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896503.